Literature DB >> 32350824

Circulating levels of fetuin-A are associated with moderate-severe hepatic steatosis in young adults.

T Filardi1, F Panimolle1, C Tiberti1, C Crescioli2, A Lenzi1, N Pallotta3, S Morano4.   

Abstract

PURPOSE: The hepatokine fetuin-A might have a role as molecular link between non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM). The aim of this study was to evaluate the association between fetuin-A and the prevalence and severity of NAFLD in a population of young adults.
METHODS: Ninety-seven adults (age 35.7 ± 12.4 years, female 64.9%), enrolled in a previous study evaluating NAFLD prevalence in the presence or absence of family history of T2DM, were included. Serum levels of fetuin-A (ELISA BioVendor, Czech Republic) and the main biochemical parameters were assessed. Presence and severity of NAFLD were evaluated by ultrasonography (Toshiba, Japan). A linear regression was run to predict fetuin-A levels and a logistic regression was performed to predict moderate-severe steatosis.
RESULTS: Fetuin-A associated inversely with age (ß - 0.12, p = 0.03) and directly with body mass index (BMI) (ß 0.5, p = 0.048), waist circumference (WC) (ß 0.3, p = 0.027), triglycerides (TG) (ß 0.1, p = 0.001) and uric acid (ß 1.7, p = 0.018), after adjustment for age and sex. In a model including age, BMI, WC, TG and uric acid, age (ß - 0.2, p = 0.002) and TG (ß 0.04, p = 0.02) were independent predictors of fetuin-A. Prevalence of steatosis was 66%. The rates of mild and moderate-severe steatosis were 50.5% and 15.5%, respectively. In the logistic model, the independent predictors of moderate-severe steatosis were fetuin-A (OR 1.22, p = 0.036), age (OR 1.17, p = 0.01) and BMI (OR 2.75, p = 0.011).
CONCLUSION: In a sample of young adults, circulating levels of fetuin-A correlated with moderate-severe NAFLD, independent of confounders, and with some metabolic parameters. Fetuin-A might be a useful marker to predict NAFLD and metabolic disorders.

Entities:  

Keywords:  Fetuin-A; Hepatic steatosis; Liver ultrasound; Moderate–severe steatosis; NAFLD; Non-alcoholic fatty liver disease; Ultrasonography

Year:  2020        PMID: 32350824     DOI: 10.1007/s40618-020-01274-w

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  30 in total

1.  Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients.

Authors:  Giovanni Targher; Lorenzo Bertolini; Roberto Padovani; Stefano Rodella; Roberto Tessari; Luciano Zenari; Christopher Day; Guido Arcaro
Journal:  Diabetes Care       Date:  2007-02-02       Impact factor: 19.112

Review 2.  Extrahepatic complications of nonalcoholic fatty liver disease.

Authors:  Matthew J Armstrong; Leon A Adams; Ali Canbay; Wing-Kin Syn
Journal:  Hepatology       Date:  2014-01-16       Impact factor: 17.425

3.  Association between diabetes, family history of diabetes, and risk of nonalcoholic steatohepatitis and fibrosis.

Authors:  Rohit Loomba; Maria Abraham; Aynur Unalp; Laura Wilson; Joel Lavine; Ed Doo; Nathan M Bass
Journal:  Hepatology       Date:  2012-07-26       Impact factor: 17.425

Review 4.  NAFLD and diabetes mellitus.

Authors:  Herbert Tilg; Alexander R Moschen; Michael Roden
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2016-10-12       Impact factor: 46.802

5.  Prevalence of suspected nonalcoholic fatty liver disease in Hispanic/Latino individuals differs by heritage.

Authors:  Eric R Kallwitz; Martha L Daviglus; Matthew A Allison; Kristen T Emory; Lihui Zhao; Mark H Kuniholm; Jinsong Chen; Natalia Gouskova; Amber Pirzada; Gregory A Talavera; Marston E Youngblood; Scott J Cotler
Journal:  Clin Gastroenterol Hepatol       Date:  2014-09-15       Impact factor: 11.382

Review 6.  Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.

Authors:  Zobair M Younossi; Aaron B Koenig; Dinan Abdelatif; Yousef Fazel; Linda Henry; Mark Wymer
Journal:  Hepatology       Date:  2016-02-22       Impact factor: 17.425

Review 7.  Pathophysiology and Mechanisms of Nonalcoholic Fatty Liver Disease.

Authors:  Joel T Haas; Sven Francque; Bart Staels
Journal:  Annu Rev Physiol       Date:  2015-11-30       Impact factor: 19.318

Review 8.  Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease.

Authors:  Chris Estes; Homie Razavi; Rohit Loomba; Zobair Younossi; Arun J Sanyal
Journal:  Hepatology       Date:  2017-12-01       Impact factor: 17.425

Review 9.  Pathophysiological Implication of Fetuin-A Glycoprotein in the Development of Metabolic Disorders: A Concise Review.

Authors:  Lynda Bourebaba; Krzysztof Marycz
Journal:  J Clin Med       Date:  2019-11-21       Impact factor: 4.241

10.  Plasma fetuin-A levels and the risk of type 2 diabetes.

Authors:  Norbert Stefan; Andreas Fritsche; Cornelia Weikert; Heiner Boeing; Hans-Georg Joost; Hans-Ulrich Häring; Matthias B Schulze
Journal:  Diabetes       Date:  2008-07-15       Impact factor: 9.461

View more
  5 in total

1.  Potential biomarkers in the fibrosis progression of nonalcoholic steatohepatitis (NASH).

Authors:  Z Wang; Z Zhao; Y Xia; Z Cai; C Wang; Y Shen; R Liu; H Qin; J Jia; G Yuan
Journal:  J Endocrinol Invest       Date:  2022-02-28       Impact factor: 4.256

2.  Fetuin-A in Activated Liver Macrophages Is a Key Feature of Non-Alcoholic Steatohepatitis.

Authors:  Quentin Etienne; Valérie Lebrun; Mina Komuta; Benoît Navez; Jean-Paul Thissen; Isabelle A Leclercq; Nicolas Lanthier
Journal:  Metabolites       Date:  2022-07-07

Review 3.  Molecular and pathobiological involvement of fetuin-A in the pathogenesis of NAFLD.

Authors:  Ojus Sardana; Ravi Goyal; Onkar Bedi
Journal:  Inflammopharmacology       Date:  2021-06-29       Impact factor: 4.473

4.  A case-control study to determination FBXW7 and Fetuin-A levels in patients with type 2 diabetes in Iraq.

Authors:  Suhayla K Mohammed; Ekhlass M Taha; Samer Abdulhasan Muhi
Journal:  J Diabetes Metab Disord       Date:  2021-01-21

5.  Effects of Uric Acid-Lowering Treatment on Glycemia: A Systematic Review and Meta-Analysis.

Authors:  Juan Chen; Jing Ge; Min Zha; Jun-Jun Miao; Zi-Lin Sun; Jiang-Yi Yu
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-02       Impact factor: 5.555

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.